[go: up one dir, main page]

MX2021001140A - Profármacos de gemcitabina. - Google Patents

Profármacos de gemcitabina.

Info

Publication number
MX2021001140A
MX2021001140A MX2021001140A MX2021001140A MX2021001140A MX 2021001140 A MX2021001140 A MX 2021001140A MX 2021001140 A MX2021001140 A MX 2021001140A MX 2021001140 A MX2021001140 A MX 2021001140A MX 2021001140 A MX2021001140 A MX 2021001140A
Authority
MX
Mexico
Prior art keywords
diastereoisomer
phosphate
gemcitabine
prodrug
relative
Prior art date
Application number
MX2021001140A
Other languages
English (en)
Other versions
MX391758B (es
Inventor
Christopher Mcguigan
Michaela Serpi
Magdalena Slusarczyk
Hugh Griffith
Valentina Ferrari
Original Assignee
Nucana Biomed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53499027&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2021001140(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1411253.6A external-priority patent/GB201411253D0/en
Application filed by Nucana Biomed Ltd filed Critical Nucana Biomed Ltd
Publication of MX2021001140A publication Critical patent/MX2021001140A/es
Publication of MX391758B publication Critical patent/MX391758B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

Profármaco; esta invención se relaciona con un profármaco del nucleótido monofosfato del medicamento oncológico bien conocido gemcitabina; específicamente, se relaciona con [fenil-benzoxi-L-alaninil)]-fosfato de gemcitabina cuando está presente como un diastereoisómero de fosfato único y, en particular, se relaciona con el diastereoisómero de (S) fosfato el cual proporciona un incremento notorio e inesperado en solubilidad en relación al diastereoisómero (R); el epímero de (S) fosfato también es captado de modo preferencial en soluciones de ciclodextrina con respecto al diastereoisómero (R).
MX2021001140A 2014-06-25 2015-06-25 Profármacos de gemcitabina. MX391758B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2050MU2014 2014-06-25
GBGB1411253.6A GB201411253D0 (en) 2014-06-25 2014-06-25 Prodrug
PCT/GB2015/051857 WO2015198058A1 (en) 2014-06-25 2015-06-25 Gemcitabine prodrugs

Publications (2)

Publication Number Publication Date
MX2021001140A true MX2021001140A (es) 2022-04-21
MX391758B MX391758B (es) 2025-03-21

Family

ID=53499027

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016015628A MX2016015628A (es) 2014-06-25 2015-06-25 Profarmacos de gemcitabina.
MX2021001140A MX391758B (es) 2014-06-25 2015-06-25 Profármacos de gemcitabina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016015628A MX2016015628A (es) 2014-06-25 2015-06-25 Profarmacos de gemcitabina.

Country Status (29)

Country Link
US (2) US10662213B2 (es)
EP (2) EP3757112B1 (es)
JP (2) JP6982957B2 (es)
KR (2) KR102563040B1 (es)
CN (2) CN111214480A (es)
AU (2) AU2015278899B2 (es)
CA (1) CA2945938C (es)
CL (1) CL2016003260A1 (es)
CY (1) CY1123389T1 (es)
DK (1) DK3160978T3 (es)
EA (1) EA034890B1 (es)
ES (2) ES2811268T3 (es)
HR (2) HRP20230584T1 (es)
HU (2) HUE062474T2 (es)
IL (2) IL248642B (es)
LT (1) LT3160978T (es)
ME (1) ME03817B (es)
MX (2) MX2016015628A (es)
MY (1) MY183198A (es)
NZ (2) NZ765508A (es)
PH (1) PH12016502553B1 (es)
PL (1) PL3160978T3 (es)
PT (1) PT3160978T (es)
RS (1) RS60968B1 (es)
SG (2) SG11201608808TA (es)
SI (1) SI3160978T1 (es)
SM (1) SMT202000564T1 (es)
TW (2) TWI695718B (es)
WO (1) WO2015198058A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58849B1 (sr) 2012-11-16 2019-07-31 Univ College Cardiff Consultants Ltd Smeša rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata
KR102563040B1 (ko) 2014-06-25 2023-08-02 뉴카나 피엘씨 젬시타빈 전구 약물
TWI674097B (zh) 2014-06-25 2019-10-11 英商努卡那公眾有限公司 磷酸酯衍生物之調配物
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106539810B (zh) 2015-09-16 2021-03-09 济南高合医疗科技有限公司 一种富集了nuc-1031单一异构体的组合物及其制备方法和用途
CN106543252A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
JP7038653B2 (ja) 2015-10-05 2022-03-18 ニューカナ パブリック リミテッド カンパニー 併用療法
HRP20211812T1 (hr) 2015-12-11 2022-03-04 NuCana plc Dijastereoselektivna sinteza derivata fosfata i prolijeka gemcitabina nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
WO2018019188A1 (zh) * 2016-07-23 2018-02-01 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
CN106946960A (zh) * 2017-03-29 2017-07-14 郑州泰基鸿诺医药股份有限公司 一种吉西他滨前药的晶型、制备方法、用途和药物组合物
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN110806454A (zh) * 2018-08-06 2020-02-18 江苏正大清江制药有限公司 一种盐酸吉西他滨中手性异构体的检测方法
CN110215469B (zh) * 2019-07-08 2021-11-30 绍兴市人民医院 一种治疗胆管癌的药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728575A (en) 1990-02-01 1998-03-17 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
JP2002500880A (ja) 1998-01-23 2002-01-15 ニューバイオティックス インコーポレイテッド 酵素に触媒される治療剤
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
EP1200455B1 (en) 1999-07-22 2009-04-22 Celmed Oncology (USA), Inc. Enzyme catalyzed therapeutic activation
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
MX2007009033A (es) 2005-01-27 2008-01-16 Erimos Pharmaceuticals Llc Formulaciones orales para lsuministro de butanos catecolicos incluyendo compuestos ndga.
EP1928475B1 (en) 2005-08-15 2018-05-23 Riboscience LLC Antiviral phosphoramidates of 4'-c-azido-substituted pronucleotides
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
GB0821994D0 (en) * 2008-12-02 2009-01-07 Ge Healthcare Ltd In viva imaging method
KR20110120886A (ko) 2009-01-09 2011-11-04 유니버시티 칼리지 오브 카디프 컨설턴트 리미티드 바이러스 감염 치료용 구아노신 뉴클레오사이드 화합물의 포스포라미데이트 유도체
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
KR20120086729A (ko) 2009-11-20 2012-08-03 클라비스 파마 에이에스에이 젬시타빈 유도체의 비경구적 제제
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
SI2681227T1 (sl) 2011-03-01 2016-04-29 Nucana Biomed Limited Fosforamidatni derivati 5-fluoro-2'-deoksiuridina za uporabo pri zdravljenju raka
CA2863500A1 (en) 2012-01-20 2013-07-25 Aratana Therapeutics Nv Eye drop composition
RS58849B1 (sr) * 2012-11-16 2019-07-31 Univ College Cardiff Consultants Ltd Smeša rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata
GB2517988A (en) * 2013-09-09 2015-03-11 Redx Pharma Ltd Compounds
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
JP2017504572A (ja) * 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
TWI674097B (zh) 2014-06-25 2019-10-11 英商努卡那公眾有限公司 磷酸酯衍生物之調配物
KR102563040B1 (ko) 2014-06-25 2023-08-02 뉴카나 피엘씨 젬시타빈 전구 약물
EP3172218B1 (en) 2014-07-22 2020-10-21 NuCana plc Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
EP3197456B2 (en) 2015-05-14 2023-10-11 NuCana plc Cancer treatments
JP7038653B2 (ja) 2015-10-05 2022-03-18 ニューカナ パブリック リミテッド カンパニー 併用療法
HRP20211812T1 (hr) 2015-12-11 2022-03-04 NuCana plc Dijastereoselektivna sinteza derivata fosfata i prolijeka gemcitabina nuc-1031
PL3393478T3 (pl) 2015-12-23 2020-07-13 NuCana plc Terapia skojarzona
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
WO2017109444A1 (en) 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy

Also Published As

Publication number Publication date
HRP20201264T1 (hr) 2021-02-05
IL248642B (en) 2020-03-31
NZ725205A (en) 2023-12-22
HRP20230584T1 (hr) 2023-09-15
CY1123389T1 (el) 2021-12-31
US11629164B2 (en) 2023-04-18
MX391758B (es) 2025-03-21
LT3160978T (lt) 2020-08-25
AU2019216626B2 (en) 2020-07-23
EP3757112A1 (en) 2020-12-30
TWI695718B (zh) 2020-06-11
EA034890B1 (ru) 2020-04-02
US20200262861A1 (en) 2020-08-20
MY183198A (en) 2021-02-18
EP3160978A1 (en) 2017-05-03
AU2015278899B2 (en) 2019-07-18
DK3160978T3 (da) 2020-08-17
SI3160978T1 (sl) 2020-11-30
KR102407935B1 (ko) 2022-06-10
EP3757112C0 (en) 2023-06-07
HUE053240T2 (hu) 2021-06-28
MX2016015628A (es) 2017-07-04
KR20220080220A (ko) 2022-06-14
KR102563040B1 (ko) 2023-08-02
US10662213B2 (en) 2020-05-26
CA2945938C (en) 2023-04-18
PH12016502553A1 (en) 2017-04-10
PH12016502553B1 (en) 2021-10-29
NZ765508A (en) 2023-12-22
JP6970236B2 (ja) 2021-11-24
SG10201907898SA (en) 2019-09-27
PL3160978T3 (pl) 2020-11-30
IL272724A (en) 2020-04-30
ES2811268T3 (es) 2021-03-11
EA201692312A1 (ru) 2017-04-28
US20170107246A1 (en) 2017-04-20
AU2019216626A1 (en) 2019-09-05
IL248642A0 (en) 2017-01-31
TWI758728B (zh) 2022-03-21
TW201613614A (en) 2016-04-16
ME03817B (me) 2021-04-20
JP6982957B2 (ja) 2021-12-17
IL272724B (en) 2021-06-30
CN111214480A (zh) 2020-06-02
PT3160978T (pt) 2020-08-24
KR20170043479A (ko) 2017-04-21
CL2016003260A1 (es) 2017-10-06
TW202033204A (zh) 2020-09-16
SMT202000564T1 (it) 2020-11-10
AU2015278899A1 (en) 2016-11-03
WO2015198058A1 (en) 2015-12-30
JP2020152725A (ja) 2020-09-24
CA2945938A1 (en) 2015-12-30
JP2017519014A (ja) 2017-07-13
RS60968B1 (sr) 2020-11-30
SG11201608808TA (en) 2016-11-29
EP3757112B1 (en) 2023-06-07
ES2948660T3 (es) 2023-09-15
CN106459129B (zh) 2020-03-31
HUE062474T2 (hu) 2023-11-28
CN106459129A (zh) 2017-02-22
EP3160978B1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
MX2021001140A (es) Profármacos de gemcitabina.
CL2018001591A1 (es) Compuestos útiles como inhibidores de cinasa.-
CL2019000844A1 (es) Compuesto de piridina.
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
MX378299B (es) Metodos para tratar infecciones por el virus de filoviridae.
CO2017006962A2 (es) Derivados de 2-anilinopirimidina sustituida como moudladores de egfr
BR112017013028A2 (pt) nucleosídeos, nucleotídeos e análogos dos mesmos substituídos
BR112017025398A2 (pt) formas de dosagem sólidas de palbociclib
EA201692537A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
CL2018003404A1 (es) Derivados del nucleósido de fosforamidato como agentes anticancer.
BR112015029933A2 (pt) método de produção de tagatose
BR112015029399A2 (pt) produção em etapa única de uma composição de polipropileno
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CL2017001310A1 (es) Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis
BR112018012943A2 (pt) forma cristalina de gencitabina
MX369857B (es) Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).
MX381092B (es) Inhibidores de fucosidasa.
DOP2016000142A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
IN2013MU00916A (es)
ECSP16024805A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
ECSP16024798A (es) Nuevo compuesto para el tratamiento de hipoglicemia severa
CR20150484A (es) Método de producción de compuestos de piridazinona
IN2013MU01219A (es)
EA202090269A3 (ru) Продукты гемцитабина
ES2397885A1 (es) Derivados de colismicina.